MDXG - MiMedx Group GAAP EPS of -$0.09 in-line revenue of $67.69M beats by $0.96M
- MiMedx Group press release ( NASDAQ: MDXG ): Q3 GAAP EPS of -$0.09 in-line.
- Revenue of $67.69M (+7.3% Y/Y) beats by $0.96M .
- The company expects net sales for the fourth quarter 2022 to be in a range of $73M to $76M, which reflects year over year growth in a range of 8% to 15% vs. consensus of $75.02M.
- For the full year 2022, the company expects net sales to be in a range of $266M to $269M, which reflects 11% to 12% growth on its 2021 net sales of its continuing portfolio of Advanced Wound Care products vs. consensus of $267.53M.
For further details see:
MiMedx Group GAAP EPS of -$0.09 in-line, revenue of $67.69M beats by $0.96M